Two FDA dates define the immediate future for Ultragenyx
- Record Q2 2026 revenue reached $214 million, with Evkeeza growing 50% year over year.
- The main near-term catalysts are FDA decisions for DTX401 on August 23 and UX111 on September 19.
- Angelman syndrome Phase 3 data for GTX-102 is now expected in September or October 2026.
- Management confirmed that the 2027 profitability plan depends heavily on selling priority review vouchers from the upcoming gene therapy approvals.
- The salvage value of UX143 is in question after the UK regulator indicated a new randomized trial is likely needed.
A launch story with sharp edges
Ultragenyx is in a narrow window. Its current drugs are generating real money, but the bigger bull case rests on two FDA decisions in Q3 2026. DTX401, for glycogen storage disease type Ia, has an FDA action date of August 23, 2026. UX111, for Sanfilippo syndrome type A, has an action date of September 19, 2026.
The good news is that the base business is not standing still. Q2 2026 revenue hit a record $214 million. Evkeeza was the bright spot, with quarterly sales up 50% year over year. This provides a growing cash cushion while the company waits for regulatory clarity.
The hard part is that this remains a high-risk biotech setup. UX111 already faced FDA manufacturing pushback. UX143, once a major late-stage asset, failed its Phase 3 primary endpoints in December 2025, and the UK regulatory body now suggests a whole new trial is needed before a review. Also, management recently clarified that reaching profitability in 2027 relies heavily on selling priority review vouchers from the upcoming approvals.
Finn's view is cautious because the company is not cheap on hope alone. The story can improve fast if the FDA says yes and launch demand is clear. It can also break if manufacturing questions return, or if those priority review vouchers fail to materialize and force a new round of funding.
Small patient groups, high stakes
Ultragenyx finds, develops, and sells drugs for rare and ultra-rare diseases. These are illnesses with small patient groups, so each drug may serve a limited number of people. The payoff can still be large because approved rare disease drugs often have high prices and less direct competition.
Money comes from product sales of Crysvita, Dojolvi, Evkeeza, and Mepsevii, plus partner economics in some regions. Crysvita is the main revenue driver. Ultragenyx sells directly in some markets, including parts of Latin America, and also receives revenue from partners in North America and Europe.
The company wants to reach profitability in 2027. That timeline depends on strict spending control after a February 2026 workforce reduction, and also relies on monetizing priority review vouchers for its new gene therapies. If those therapies are delayed, the profitability timeline could slip.
The moat is know-how: finding rare disease patients, running hard clinical trials, dealing with regulators, and building specialized sales teams. The weak point is that one failed trial or one FDA manufacturing issue can erase years of work.
What sells now, what could matter next
Crysvita
Crysvita treats X-linked hypophosphatemia and tumor-induced osteomalacia. It is the main revenue driver, contributing $156 million in Q2 2026.
Dojolvi
Dojolvi treats long-chain fatty acid oxidation disorders. It brought in $27 million in Q2 2026, though new generic ANDA litigation remains a legal threat.
Evkeeza
Evkeeza treats homozygous familial hypercholesterolemia. It was the strongest commercial grower in Q2 2026, with sales up 50% year over year to $21 million.
Mepsevii
Mepsevii treats MPS VII, a very rare genetic disease. It contributed $10 million in Q2 2026.
DTX401
DTX401 is a gene therapy for glycogen storage disease type Ia. Its BLA is under FDA review, with an action date of August 23, 2026.
UX111
UX111 is a gene therapy for Sanfilippo syndrome type A. The resubmitted BLA is under review, with an action date of September 19, 2026.
GTX-102
GTX-102 is an antisense drug for Angelman syndrome. Pivotal Phase 3 data is expected in September or October 2026.
UX143
UX143 is being studied for osteogenesis imperfecta. Its Phase 3 trials failed, and the UK MHRA believes a new randomized study is needed before review.
Q2 product mix leans heavily on Crysvita
The mix below uses Q2 2026 total revenue of $214 million. Crysvita accounted for $156 million, Dojolvi for $27 million, Evkeeza for $21 million, and Mepsevii for $10 million.
What could go wrong
FDA delay or rejection for gene therapies
High impact · Medium oddsThe two biggest 2026 catalysts are FDA decisions for DTX401 and UX111. A rejection or long delay would push out the launch story and ruin the 2027 profit plan, which relies on priority review voucher sales.
Profitability plan depends on voucher sales
High impact · Medium oddsUltragenyx expects to reach profitability for 2027, but management stated this target relies on selling priority review vouchers associated with DTX401 and UX111. If approvals slip or voucher prices drop, financing pressure will return.
Manufacturing questions come back
High impact · Medium oddsGene therapies are hard to make at commercial quality. The FDA previously cited observations at Ultragenyx's gene therapy manufacturing facility for UX111. Similar issues could affect the final approval or launch supply.
UX143 salvage value continues to fall
Medium impact · High oddsUX143 failed its Phase 3 endpoints in December 2025. The UK MHRA indicated a new randomized study is likely needed for review. Even if the FDA is open to alternative analyses, the regulatory path is steep and expensive.
Dojolvi generic challenge
Medium impact · Medium oddsSomerset filed an ANDA seeking approval for a generic version of Dojolvi, and Ultragenyx filed a patent infringement suit. A faster or worse-than-expected legal outcome could pressure a product that still contributes meaningful sales.
In one breath
What does Ultragenyx do?
Ultragenyx develops and sells treatments for rare and ultra-rare diseases. Its current commercial drugs include Crysvita, Dojolvi, Evkeeza, and Mepsevii.
Why are the 2026 FDA dates important for RARE stock?
The FDA action dates for DTX401 and UX111 will decide whether Ultragenyx adds two new gene therapy launches. Those decisions and their attached priority review vouchers are required for the 2027 profitability plan.
What happened to UX143?
UX143 missed the primary endpoints in two Phase 3 studies in December 2025. The UK MHRA recently indicated a new trial may be needed, though the FDA is still reviewing alternative data analyses.
Is Ultragenyx profitable?
The company expects to keep losing money in the near term. It targets profitability for the year 2027, but that relies on successfully selling priority review vouchers from upcoming drug approvals.
